Brokerages Set Atossa Genetics Inc. (NASDAQ:ATOS) Target Price at $20.33

Atossa Genetics Inc. (NASDAQ:ATOS) has earned a consensus recommendation of “Hold” from the five analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.3333.

Several research firms recently issued reports on ATOS. Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Rodman & Renshaw began coverage on Atossa Genetics in a research report on Tuesday, July 7th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen raised Atossa Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds have recently modified their holdings of ATOS. Geode Capital Management LLC boosted its holdings in shares of Atossa Genetics by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after purchasing an additional 9,627 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics during the second quarter worth $26,000. JPMorgan Chase & Co. grew its holdings in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares in the last quarter. Bank of America Corp DE grew its holdings in Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares in the last quarter. Finally, &PARTNERS purchased a new stake in Atossa Genetics in the 4th quarter valued at $25,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Stock Performance

NASDAQ:ATOS opened at $2.58 on Wednesday. The stock has a market capitalization of $25.75 million, a PE ratio of -0.83 and a beta of 1.29. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35. The company has a fifty day moving average of $2.34 and a two-hundred day moving average of $3.92.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.07. Research analysts forecast that Atossa Genetics will post -3.95 earnings per share for the current year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.